Meridian Bioscience Other Current Liabilities

Meridian Bioscience (VIVO) currently reports a other current liabilities of $61M as of December 2022. That compares with $34M in the prior-year period — up 81.6% year over year. Use the charts on this page to explore Meridian Bioscience's other current liabilities history and peer comparisons.

Meridian Bioscience's other current liabilities increased from $34M to $61M — a 81.6% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Meridian Bioscience reported $61M in other current liabilities as of December 2022. That compares with $34M in the prior-year period — up 81.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $61M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Meridian Bioscience, and consider following VIVO for alerts when major investors trade the stock.

Meridian Bioscience is classified in the Healthcare sector. On other current liabilities, it currently shows $61M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VIVO with unrelated industries.